Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Weiss Website

Jonathan M. Weiss, Ph.D.

Selected Publications

1)  Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.
Effective chemoimmunotherapy with anti-TGFß antibody and cyclophosphamide in a mouse model of breast cancer.
PLoS ONE. 9: e85398, 2014.
2)  Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.
NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Int. J. Cancer. 132: 9-18, 2013.
3)  Jiang Q, Weiss JM, Wiltrout RH.
A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.
Oncoimmunology. 1: 115-117, 2012.
4)  Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.
Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.
Blood. 119: 3073-83, 2012.
5)  Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.
Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.
PLoS ONE. 7: e33303, 2012.
6)  Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.
Cancer Res. 71: 2718-27, 2011.
7)  Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ.
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation.
Biol. Blood Marrow Transplant. 17: 1754-64, 2011.
8)  Chan T, Wiltrout RH, Weiss JM.
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.
Int. Immunopharmacol. 11: 879-89, 2011.
9)  Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH.
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Cancer Res. 71: 4074-84, 2011.
10)  Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH.
The split personality of NKT cells in malignancy, autoimmune and allergic disorders.
Immunotherapy. 3: 1167-84, 2011.
11)  Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH.
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.
J. Exp. Med. 207: 2455-67, 2010.
12)  Subleski JJ, Hall VL, Wolfe TB, Scarzello AJ, Weiss JM, Chan T, Hodge DL, Back TC, Ortaldo JR, Wiltrout RH.
TCR-Dependent and -Independent Activation Underlie Liver-Specific Regulation of NKT Cells.
J. Immunol. 186: 838-47, 2010.
13)  Subleski JJ, Wiltrout RH, Weiss JM.
Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.
J. Autoimmun. 33: 275-81, 2009.
14)  Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Proc. Natl. Acad. Sci. U.S.A. 106: 19455-60, 2009.
15)  Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.
Nitric oxide is a key component in inflammation-accelerated tumorigenesis.
Cancer Res. 68: 7130-6, 2008.
16)  Alderson KL, Zhou Q, Berner V, Wilkins DE, Weiss JM, Blazar BR, Welniak LA, Wiltrout RH, Redelman D, Murphy WJ.
Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
J. Immunol. 180: 2981-8, 2008.
17)  Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ.
IFN-gamma mediates CD4(+) T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Nat. Med. 13: 354-60, 2007.
18)  Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.
Immunotherapy of cancer by IL-12-based cytokine combinations.
Expert Opin. Biol. Ther. 7: 1705-21, 2007.
19)  Li LH, Biagi E, Allen C, Shivakumar R, Weiss JM, Feller S, Yvon E, Fratantoni JC, Liu LN.
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Cancer Gene Ther. 13: 215-24, 2006.
20)  Shorts L, Weiss JM, Lee JK, Welniak LA, Subleski J, Back T, Murphy WJ, Wiltrout RH.
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
J. Immunol. 176: 6543-52, 2006.
21)  Weiss JM, Allen C, Shivakumar R, Feller S, Li LH, Liu LN.
Efficient responses in a murine renal tumor model by electroloading dendritic cells with whole-tumor lysate.
J. Immunother. 28: 542-50, 2005.
22)  Weiss JM, Shivakumar R, Feller S, Li LH, Hanson A, Fogler WE, Fratantoni JC, Liu LN.
Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells.
Cancer Gene Ther. 11: 346-53, 2004.
23)  Li LH, Shivakumar R, Feller S, Allen C, Weiss JM, Dzekunov S, Singh V, Holaday J, Fratantoni J, Liu LN.
Highly efficient, large volume flow electroporation.
Technol. Cancer Res. Treat. 1: 341-50, 2002.
24)  Manabe R, Whitmore L, Weiss JM, Horwitz AR.
Identification of a novel microtubule-associated protein that regulates microtubule organization and cytokinesis by using a GFP-screening strategy.
Curr. Biol. 12: 1946-51, 2002.
25)  Barry WT, Boudignon-Proudhon C, Shock DD, McFadden A, Weiss JM, Sondek J, Parise LV.
Molecular basis of CIB binding to the integrin alpha IIb cytoplasmic domain.
J. Biol. Chem. 277: 28877-83, 2002.
26)  Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW.
Mechanisms of leukocyte trafficking into the CNS.
J. Neurovirol. 6 Suppl 1: S82-5, 2000.
27)  Weiss JM, Nath A, Major EO, Berman JW.
HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes.
J. Immunol. 163: 2953-9, 1999.
28)  Weiss JM, Cuff CA, Berman JW.
TGF-beta downmodulates cytokine-induced monocyte chemoattractant protein (MCP)-1 expression in human endothelial cells. A putative role for TGF-beta in the modulation of TNF receptor expression.
Endothelium. 6: 291-302, 1999.
29)  Weiss JM, Berman JW.
Astrocyte expression of monocyte chemoattractant protein-1 is differentially regulated by transforming growth factor beta.
J. Neuroimmunol. 91: 190-7, 1998.
30)  Weiss JM, Downie SA, Lyman WD, Berman JW.
Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier.
J. Immunol. 161: 6896-903, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/16/2014.